Springer Nature Switzerland AG

Translational Research Methods for the Metabolic Continuum: A Focus on Early Phase Clinical Drug Development

Translational Research Methods for the Metabolic Continuum: A Focus on Early Phase Clinical Drug Development

💎 Earn 764 Points (£7.64) on this item.

Regular price £152.92 GBP
Regular price £179.99 GBP Sale price £152.92 GBP
Sale Sold out
Taxes included. Shipping calculated at checkout.

YOU SAVE £27.07

  • Condition: Brand new
  • UK Delivery times: Usually arrives within 2 - 3 working days
  • UK Shipping: Fee starts at £2.39. Subject to product weight & dimension

Bulk ordering. Want 15 or more copies? Get a personalised quote and bigger discounts. Learn more about bulk orders.

  • More about Translational Research Methods for the Metabolic Continuum: A Focus on Early Phase Clinical Drug Development
In this 3rd edition, we position metabolic fatty liver disease (MAFLD) more prominently both as a component and driver of a metabolic continuum of non-communicable disorders. These include obesity, diabetes, cardiovascular, and renal disease.  All share common risk factors and are interconnected via complex – and often bidirectional – pathological processes. The pivotal position of MAFLD reflects increasing awareness in recent years of (a) intersections between metabolic liver disease and the broader spectrum of cardiometabolic disorders and (b) the unmet need for effective new pharmacotherapies.  Evidence from clinical trials of medications originally developed to treat obesity and diabetes points to the need for practical non-invasive methods for quantifying therapeutic effects on hepatic steatosis.  An intense drug development effort continues aimed at the clinically important subtype of non-alcoholic steatohepatitis (NASH) which carriesan increased risk of fibrosis, cirrhosis, and hepatocellular carcinoma. Moreover, MAFLD/NASH is recognized as a multisystem disease with myriad extrahepatic manifestations. The 3rd edition will update all chapters with particular emphasis on expanding the chapters on hepato-cardio-renal and functional imaging; the chapter on isotopic tracer methodology will also be strengthened.  Relevant new chapters in a new section will address the future prospects for biomarkers to include proteomics, metabolomics, and genomics.  The potential of computational modeling in translational research will be covered alongside the value of real-world data in drug development and strategies for personalized precision management of diseases in the metabolic continuum. The book will continue our objective – established in the earlier editions – to remain at the forefront of clinical science that facilitates paradigm changes and provides leadership in translational research for cardiometabolic disorders.
  • Publication date: 13 September 2026
  • Page count: 642
  • Dimensions: Height 254 mm; Width 178 mm
  • Publisher: Springer Nature Switzerland AG
  • Format: Hardback
  • ISBN-13: 9783032304995

UK and International shipping information

UK Delivery and returns information:

  • Delivery within 2 - 3 days when ordering in the UK.
  • Shipping fee for UK customers from £2.39. Fully tracked shipping service available.
  • Returns policy: Return within 30 days of receipt for full refund.

International deliveries:

Shulph Ink now ships to Australia, Belgium, Canada, France, Germany, Ireland, Italy, India, Luxembourg Saudi Arabia, Singapore, Spain, Netherlands, New Zealand, United Arab Emirates, United States of America.

  • Delivery times: within 5 - 10 days for international orders.
  • Shipping fee: charges vary for overseas orders. Only tracked services are available for most international orders. Some countries have untracked shipping options.
  • Customs charges: If ordering to addresses outside the United Kingdom, you may or may not incur additional customs and duties fees during local delivery.
View full details